NASDAQ:HZNP
Delisted

Horizon Therapeutics Public Company Stock News

etoro logo Buy HZNP
*Your capital is at risk
$116.30
+0 (+0%)
At Close: Jan 04, 2024
Horizon Therapeutics announces new pooled efficacy data for TEPEZZA (teprotumumab-trbw) for the treatment of Thyroid Eye Disease (TED).
New York, March 31, 2020 -- Reportlinker.com announces the release of the report "Global Osteoarthritis Pain Drug Market - Premium Insight, Competitive News Feed Analysis,.
Pharmaceutical stocks dipped by a double-digit percentage in the first three months of 2020, trailing their biotech brethren. Still, there are standout companies in the industry group.
Shares of Horizon Therapeutics PLC (NASDAQ:HZNP) have been assigned a consensus rating of “Buy” from the seventeen ratings firms that are presently covering the firm, Marketbeat reports. Four anal
Axa lifted its position in Horizon Therapeutics PLC (NASDAQ:HZNP) by 2.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC).
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Therapeutics plc (Nasdaq: HZNP) announced today that it, in partnership with Illinois Governor JB Pritzker, has provided $500,000 to the Illinois COVID-19 Response Fund and $500,000 to the Ill
AQR Capital Management LLC increased its holdings in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 11.7% in the 4th quarter, according to its most recent disclosure with the Securities and Excha
FDA has denied Acer's appeal from the CRL issued last June in response to the NDA filed for EDSIVO, a potential treatment for vEDS patients with COL3A1 mutation
Horizon Therapeutics (NASDAQ:HZNP) had its price objective cut by investment analysts at Bank of America from $45.00 to $42.00 in a report released on Monday, AnalystRatings.com reports. The brokerage
Advisor Group Inc. increased its holdings in Horizon Therapeutics PLC (NASDAQ:HZNP) by 32.9% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. T
In a report released today, Jason Gerberry from Merrill Lynch maintained a Buy rating on Horizon Therapeutics ( HZNP – Research Report ), with a price target of $42.00 . The company’s shares close
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE